Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics
Advanced Healthcare Materials · 2026-05 · 15 (19)
DOI: 10.1002/adhm.202505340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 18.02.2026. Verfasst von Honglei Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Beijing, P. R. China. Hauptthemen laut MEDLINE: Lipids, Nanoparticles, RNA, RNA, Messenger. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 244 Literaturangaben.
Abstract (Originalsprache)
Lipid nanoparticle (LNP)‐mRNA technology has profoundly transformed the biomedical landscape, establishing itself as a highly versatile and powerful platform with substantial therapeutic and prophylactic potential across a wide range of diseases. This review summarizes recent advances in LNP delivery systems aimed at unlocking the full potential of RNA therapeutics. Key focuses include: 1) the design and screening of novel lipid molecules to improve mRNA delivery efficiency and targeting; 2) optimization of administration routes, LNP surface functionalization, and formulation components; and 3) advances in lyophilized LNP formulations. We also highlight the growing integration of artificial intelligence (AI) for designing next‐generation LNPs and overcoming existing translational barriers. Furthermore, the review provides a comprehensive overview of clinical applications of RNA‐LNPs in infectious diseases, cancer immunotherapy, gene therapy, cell‐based therapeutics, and RNAi‐LNP therapeutics, offering systematic strategies to enhance delivery efficacy and translational capacity. Finally, we discuss the future directions and unresolved challenges, including multimodal fusion delivery methodology of LNP and non‐LNP carriers, the interdisciplinary integration of various fields, and the bottleneck of extrahepatic delivery strategies, offering systematic insights into the translational pathway of mRNA‐LNP therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd., Beijing, P. R. China.
- Hangzhou Tianlong Pharmaceutical Co., Ltd., Hangzhou, P. R. China.
ORCID-Profile: Honglei Zhang, Jingxuan Ma, Lijie Jin, Yuqing Ma, Gengshen Song
Zitieren
APA
Zhang, H., Han, S., Zhang, X., Ma, J., Jin, L., Wang, Y., Ma, Y., Ma, T., Yu, F., & Song, G. (2026). Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics. Advanced Healthcare Materials, 15(19). https://doi.org/10.1002/adhm.202505340
Vancouver
Zhang H, Han S, Zhang X, Ma J, Jin L, Wang Y, et al. Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics. Advanced Healthcare Materials. 2026;15(19). doi:10.1002/adhm.202505340
BibTeX
@article{Zhang2026,
author = {Zhang, Honglei and Han, Shaowei and Zhang, Xueyan and Ma, Jingxuan and Jin, Lijie and Wang, Yanfeng and Ma, Yuqing and Ma, Teng and Yu, Fei and Song, Gengshen},
title = {Novel Lipid Nanoparticle (LNP) Delivery Systems Enabling the Advancement of RNA Therapeutics},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {19},
doi = {10.1002/adhm.202505340}
}
EUVIMED